CMC(SH:603122)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥267,190,714.93, representing a decrease of 13.25% compared to the same period last year[5] - Net profit attributable to shareholders was ¥9,222,339.66, down 39.09% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥9,797,345.31, a decrease of 37.00% compared to the previous year[5] - Basic and diluted earnings per share were both ¥0.02, reflecting a decline of 60.00% year-on-year[5] - Total operating revenue for Q1 2023 was ¥267,190,714.93, a decrease of 13.3% compared to ¥307,984,973.42 in Q1 2022[18] - Net profit for Q1 2023 was ¥9,111,154.02, a decline of 40.0% from ¥15,156,422.19 in Q1 2022[19] - Earnings per share for Q1 2023 were ¥0.02, compared to ¥0.05 in Q1 2022[20] Cash Flow and Liquidity - The net cash flow from operating activities was -¥113,986,510.74, indicating a significant cash outflow[5] - In Q1 2023, the company's cash inflow from operating activities was CNY 254,639,895.29, a decrease of 3.8% compared to CNY 264,643,033.90 in Q1 2022[22] - The net cash outflow from operating activities was CNY -113,986,510.74, worsening from CNY -67,054,010.90 in the same period last year[22] - The company's cash and cash equivalents decreased significantly, impacting liquidity ratios[19] - Cash inflow from financing activities totaled CNY 112,061,541.77, a decrease of 75% from CNY 448,199,884.89 in Q1 2022[23] - The net cash flow from financing activities was CNY 30,656,394.52, down from CNY 326,273,822.10 in the same quarter last year[23] - The company's cash and cash equivalents at the end of Q1 2023 were CNY 228,813,378.42, down from CNY 392,401,162.51 at the end of Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,507,131,250.60, down 3.33% from the end of the previous year[5] - Total assets as of Q1 2023 amounted to ¥1,507,131,250.60, a decrease from ¥1,559,065,109.86 in the previous year[16] - Total liabilities for Q1 2023 were ¥321,349,173.08, down from ¥380,491,021.65 in Q1 2022[16] - Cash and cash equivalents as of March 31, 2023, amounted to RMB 241,769,403.33, down from RMB 326,855,769.22 as of December 31, 2022[14] - Accounts receivable increased to RMB 794,485,889.13 from RMB 746,897,311.83 year-over-year[14] - Total current assets decreased to RMB 1,354,330,563.06 from RMB 1,411,341,524.19[14] - Inventory as of March 31, 2023, was RMB 201,481,116.36, slightly down from RMB 204,822,603.19[14] Shareholder Information - Total number of common shareholders at the end of the reporting period was 40,762[11] - The largest shareholder, 合富（香港）控股有限公司, holds 218,937,885 shares, representing 55.00% of total shares[11] - The report indicates that there are no known relationships or concerted actions among the top shareholders[12] Operational Insights - The decline in net profit was primarily due to reduced service volume from end hospitals and decreased reagent procurement by customers[8] - The company's COVID-19 testing business had a minimal impact on the overall net profit, with only ¥760,000 in gross profit from related operations in the previous year[8] - The company expanded its sales, marketing, and R&D teams, leading to increased employee compensation and marketing expenses[8] - The company has not disclosed any new product or technology developments in the current report[13] - There are no significant mergers or acquisitions reported during the period[13] - The company has not provided specific future guidance or market expansion strategies in the current report[13] - Research and development expenses increased to ¥616,123.18 in Q1 2023 from ¥459,910.51 in Q1 2022, reflecting a focus on innovation[19] - The company reported a decrease in other comprehensive income, with a net amount of -¥1,903,164.70 in Q1 2023 compared to -¥729,314.51 in Q1 2022[20] - The company is exploring market expansion strategies to recover from the decline in revenue and profit margins[19]